Sentieon
Sentieon, founded in 2014, develops highly optimized bioinformatics secondary analysis software for genomics data processing with exceptional accuracy and computing efficiency. Their flagship product, DNAscope, supports both short and long read sequencing platforms, offering fast turnaround times (processing 30x whole genome sequencing data in under 30 minutes) and cost-effective solutions deployable on generic CPU-based systems. Sentieon's software is a drop-in replacement for popular tools like BWA-MEM, STAR, Minimap2, GATK, and Mutect2, providing accelerated performance without compromising accuracy. The company serves genome sequencing service providers, molecular diagnostic companies, pharmaceutical and biotech firms, hospitals, cancer centers, direct-to-consumer genomics companies, and academic research institutes. Their tools have processed millions of samples totaling over 2700 petabases of sequence data and have won multiple awards for accuracy and innovation, including top placements in precisionFDA challenges and the ICGC-TCGA DREAM Mutation Calling Challenge. Sentieon's business model is primarily SaaS, offering scalable, deployable, and upgradable software-only solutions that reduce compute costs and improve data processing speed and consistency in precision medicine applications.
Sentieon
Sentieon, founded in 2014, develops highly optimized bioinformatics secondary analysis software for genomics data processing with exceptional accuracy and computing efficiency. Their flagship product, DNAscope, supports both short and long read sequencing platforms, offering fast turnaround times (processing 30x whole genome sequencing data in under 30 minutes) and cost-effective solutions deployable on generic CPU-based systems. Sentieon's software is a drop-in replacement for popular tools like BWA-MEM, STAR, Minimap2, GATK, and Mutect2, providing accelerated performance without compromising accuracy. The company serves genome sequencing service providers, molecular diagnostic companies, pharmaceutical and biotech firms, hospitals, cancer centers, direct-to-consumer genomics companies, and academic research institutes. Their tools have processed millions of samples totaling over 2700 petabases of sequence data and have won multiple awards for accuracy and innovation, including top placements in precisionFDA challenges and the ICGC-TCGA DREAM Mutation Calling Challenge. Sentieon's business model is primarily SaaS, offering scalable, deployable, and upgradable software-only solutions that reduce compute costs and improve data processing speed and consistency in precision medicine applications.